PE20120342A1 - Formulacion de anticuerpo - Google Patents

Formulacion de anticuerpo

Info

Publication number
PE20120342A1
PE20120342A1 PE2011001179A PE2011001179A PE20120342A1 PE 20120342 A1 PE20120342 A1 PE 20120342A1 PE 2011001179 A PE2011001179 A PE 2011001179A PE 2011001179 A PE2011001179 A PE 2011001179A PE 20120342 A1 PE20120342 A1 PE 20120342A1
Authority
PE
Peru
Prior art keywords
formulation
antibody
amount
sodium phosphate
sodium
Prior art date
Application number
PE2011001179A
Other languages
English (en)
Inventor
Joachim Momm
Hans-Joachim Wallny
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120342(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20120342A1 publication Critical patent/PE20120342A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UNA FORMULACION FARMACEUTICA QUE COMPRENDE: A) UN ANTICUERPO PARA IL-1 BETA TAL COMO ACZ885 EN UNA CANTIDAD ENTRE 10-150 mg/mL, B) UN SISTEMA REGULADOR SELECIONADO DE CITRATO, HISTIDINA, SUCCINATO DE SODIO, FOSFATO DE SODIO Y/O POTASIO. COMPRENDE ADEMAS UN ESTABILIZANTE SELECCIONADO DE SACAROSA, TREHALOSA, MANITOL, SORBITOL Y CLORHIDRATO DE ARGININA EN UNA CANTIDAD DE 50-300nM. DICHA FORMULACION TIENE UN pH DE 5.5-7.5, SIENDO UTIL EN EL TRATAMIENTO DE LOS RECEPTORES DE TRASPLANTES DE CORAZON, PULMON, HIGADO, RINON, ENFERMEDADES AUTOINMUNES Y CONDICIONES INFLAMATORIAS, ASMA, BRONQUITIS, ENTRE OTROS
PE2011001179A 2008-12-10 2009-12-09 Formulacion de anticuerpo PE20120342A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08170884A EP2196476A1 (en) 2008-12-10 2008-12-10 Antibody formulation

Publications (1)

Publication Number Publication Date
PE20120342A1 true PE20120342A1 (es) 2012-04-24

Family

ID=40637230

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001179A PE20120342A1 (es) 2008-12-10 2009-12-09 Formulacion de anticuerpo

Country Status (32)

Country Link
US (3) US20110236398A1 (es)
EP (4) EP2196476A1 (es)
JP (5) JP6143416B2 (es)
KR (2) KR101762966B1 (es)
CN (3) CN102245639B (es)
AU (1) AU2009324371B2 (es)
BR (1) BRPI0922730A2 (es)
CA (1) CA2745938C (es)
CL (1) CL2011001406A1 (es)
CO (1) CO6361952A2 (es)
CY (2) CY1117735T1 (es)
DK (2) DK3072906T3 (es)
EC (1) ECSP11011192A (es)
ES (2) ES2900624T3 (es)
HK (1) HK1159130A1 (es)
HR (2) HRP20211899T1 (es)
HU (2) HUE028408T2 (es)
IL (3) IL264316B2 (es)
LT (1) LT3072906T (es)
MA (1) MA33023B1 (es)
MX (1) MX2011006242A (es)
MY (2) MY166050A (es)
NZ (1) NZ592918A (es)
PE (1) PE20120342A1 (es)
PL (2) PL2376533T3 (es)
PT (2) PT3072906T (es)
RU (2) RU2563179C2 (es)
SI (2) SI3072906T1 (es)
SM (1) SMT201600222B (es)
TN (1) TN2011000229A1 (es)
WO (1) WO2010066762A1 (es)
ZA (1) ZA201103362B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
LT2542257T (lt) 2010-03-01 2017-11-27 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
CN102905692B (zh) 2010-05-28 2015-09-16 诺沃—诺迪斯克有限公司 包含抗体和防腐剂的稳定的多剂量组合物
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AR083035A1 (es) 2010-09-17 2013-01-30 Baxter Int ESTABILIZACION DE INMUNOGLOBULINAS MEDIANTE UNA FORMULACION ACUOSA CON HISTIDINA A pH ACIDO DEBIL A NEUTRO, COMPOSICION ACUOSA DE INMUNOGLOBULINA
CA3162352A1 (en) 2010-10-01 2012-04-05 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
AR085911A1 (es) 2011-03-16 2013-11-06 Sanofi Sa Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
FI123630B (fi) 2011-10-24 2013-08-30 Teknologian Tutkimuskeskus Vtt Menetelmä NFC-kalvojen valmistamiseksi alustoille
AP2014007680A0 (en) 2011-12-02 2014-06-30 Novartis Ag Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
CN104271122A (zh) * 2012-02-16 2015-01-07 桑塔鲁斯股份有限公司 抗vla1(cd49a)抗体药物组合物
BR112014022855A2 (pt) * 2012-03-16 2017-07-18 Regeneron Pharma animal não humano geneticamente modificado, mamífero geneticamente modificado, e, método para fabricar um animal não humano
AU2013243946A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
IN2015KN00657A (es) * 2012-09-20 2015-07-17 Morphosys Ag
CA2891556A1 (en) * 2012-11-16 2014-05-22 Novartis Ag Use of il-1 beta binding antibodies for treating peripheral arterial disease
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
AR095496A1 (es) 2013-03-15 2015-10-21 Bayer Healthcare Llc Formulaciones de anticuerpos anti-receptor de prolactina
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2950392A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
AU2015310879A1 (en) * 2014-09-03 2017-03-02 Medimmune Limited Stable anti-IL-4R-alpha antibody formulation
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
US11058769B2 (en) * 2015-12-07 2021-07-13 Merck Patent Gmbh Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab
US20210292404A1 (en) * 2016-07-21 2021-09-23 Novartis Ag Use of il-1beta binding antibody canakinumab for treating or allevating symptoms pulmonary sarcoidosis
CN109862880A (zh) * 2016-09-27 2019-06-07 德国费森尤斯卡比有限公司 液体药物组合物
MY195529A (en) 2016-11-18 2023-01-30 Astellas Pharma Inc Novel Anti-Human MUC1 Antibody Fab Fragment
JP2020524694A (ja) * 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
BR112020004903A2 (pt) * 2017-09-13 2020-09-15 Novartis Ag uso de anticorpos de ligação de il-1b para o tratamento de hepatite alcoólica
SG11202103670XA (en) 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
CA3129901A1 (en) * 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
WO2022135395A1 (zh) * 2020-12-22 2022-06-30 百奥泰生物制药股份有限公司 稳定的抗体制剂及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es) 1995-01-23 1997-01-28 Hoffmann La Roche Proteina accesoria del receptor de la interleucina 1
BR9609743A (pt) 1995-07-27 1999-03-02 Genentech Inc Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
JP4955185B2 (ja) * 2000-06-29 2012-06-20 アボット・ラボラトリーズ 二重特異性抗体ならびに作製方法および使用方法
AU2001276737A1 (en) * 2000-08-04 2002-02-18 Chugai Seiyaku Kabushiki Kaisha Protein injection preparations
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
ATE556591T1 (de) * 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
LT2335725T (lt) * 2003-04-04 2017-01-25 Genentech, Inc. Didelės koncentracijos antikūno ir baltymo kompozicijos
JP2008528638A (ja) * 2005-01-28 2008-07-31 ワイス ポリペプチドの安定化液体処方
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US20090110681A1 (en) * 2005-03-08 2009-04-30 Pfizer, Inc. Anti-M-CSF Antibody Compositions
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
BRPI0617830B8 (pt) 2005-10-26 2021-05-25 Novartis Ag uso de um anticorpo de ligação il-1beta e composições farmacêuticas compreendendo o mesmo
CN201044845Y (zh) * 2006-10-28 2008-04-09 李开元 自动注射器
AU2007331712A1 (en) * 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
BRPI0809112A2 (pt) * 2007-03-22 2014-08-26 Imclone Llc Formulações estáveis de anticorpos
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery

Also Published As

Publication number Publication date
JP6143416B2 (ja) 2017-06-07
RU2563179C2 (ru) 2015-09-20
EP2376533B1 (en) 2016-03-30
HK1159130A1 (zh) 2012-07-27
JP7286595B2 (ja) 2023-06-05
IL212922B (en) 2019-02-28
WO2010066762A1 (en) 2010-06-17
KR20170044211A (ko) 2017-04-24
KR20120009421A (ko) 2012-01-31
ES2579835T3 (es) 2016-08-17
MA33023B1 (fr) 2012-02-01
ZA201103362B (en) 2012-01-25
SI2376533T1 (sl) 2016-07-29
PT2376533T (pt) 2016-07-13
HUE028408T2 (en) 2016-12-28
MY157772A (en) 2016-07-29
NZ592918A (en) 2012-12-21
IL212922A0 (en) 2011-07-31
HRP20160754T1 (hr) 2016-08-12
JP2012511540A (ja) 2012-05-24
JP2023109938A (ja) 2023-08-08
CA2745938A1 (en) 2010-06-17
EP2376533A1 (en) 2011-10-19
PT3072906T (pt) 2021-12-14
MX2011006242A (es) 2011-06-24
SI3072906T1 (sl) 2022-01-31
ECSP11011192A (es) 2011-08-31
US8623367B2 (en) 2014-01-07
RU2011127913A (ru) 2013-01-20
JP2015231997A (ja) 2015-12-24
EP3792282A1 (en) 2021-03-17
CN102245639A (zh) 2011-11-16
CA2745938C (en) 2018-04-24
ES2900624T3 (es) 2022-03-17
JP2020203889A (ja) 2020-12-24
RU2015132431A3 (es) 2018-12-24
EP2196476A1 (en) 2010-06-16
DK3072906T3 (da) 2021-12-13
PL2376533T3 (pl) 2016-09-30
SMT201600222B (it) 2016-08-31
JP2018168158A (ja) 2018-11-01
IL264316A (en) 2019-02-28
CY1124844T1 (el) 2022-11-25
IL264316B1 (en) 2023-09-01
CO6361952A2 (es) 2012-01-20
TN2011000229A1 (en) 2012-12-17
CN104399076B (zh) 2021-09-14
CN102245639B (zh) 2014-12-24
HRP20211899T1 (hr) 2022-03-04
EP3072906A1 (en) 2016-09-28
KR101762966B1 (ko) 2017-07-31
RU2745601C2 (ru) 2021-03-29
CY1117735T1 (el) 2017-05-17
HUE056626T2 (hu) 2022-02-28
CL2011001406A1 (es) 2012-03-30
DK2376533T3 (en) 2016-06-27
EP3072906B1 (en) 2021-09-08
US20110236398A1 (en) 2011-09-29
CN104399076A (zh) 2015-03-11
LT3072906T (lt) 2021-12-27
IL276622A (en) 2020-09-30
CN114225022A (zh) 2022-03-25
MY166050A (en) 2018-05-22
PL3072906T3 (pl) 2022-01-24
US20120315285A1 (en) 2012-12-13
RU2015132431A (ru) 2018-12-24
US20200384108A1 (en) 2020-12-10
AU2009324371A1 (en) 2011-06-23
AU2009324371B2 (en) 2013-10-10
BRPI0922730A2 (pt) 2018-11-06
IL264316B2 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
PE20120342A1 (es) Formulacion de anticuerpo
CL2020000468A1 (es) Uso de una formulación estable que comprende una enzima de reemplazo para la enzima lisosomal (divisional solicitud 201801220)
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
CL2012001966A1 (es) Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis.
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
CL2020000810A1 (es) Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas.
AR082381A1 (es) Composicion acuosa que contiene bromhexina
RS52913B (en) SUBcutaneous FORMULATION OF ANTI-HER2 ANTIBODIES
CR9832A (es) Compuestos de pirimidina amida como inhibidores de pgds
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
RS54769B1 (sr) Visoko koncentrovane farmaceutske formulacije koje sadrže anti-cd20 antitelo
ES2650689T3 (es) Administración de agentes terapéuticos al sistema nervioso central
CR8904A (es) Formulaciones estabilizadoras
AR083034A1 (es) ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
NZ605873A (en) Methods and compositions for cns delivery of arylsulfatase a
CR10842A (es) Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico por imagenes
AR098168A1 (es) Formulación estable de insulina glulisina
AR082422A1 (es) Composicion detergente liquida
EA201301334A1 (ru) Меченные радиоактивными изотопами ингибиторы глутаминилциклазы
AR096705A1 (es) Composición que comprende ácido glutámico-n,n-diacetato (glda), agua y enzima
BR112016007371A2 (pt) compostos para cromatografia por afinidade e para extensão da meia-vida de um agente terapêutico
AR091888A1 (es) Compuestos de urea y su uso como inhibidores de enzimas
PA8747601A1 (es) Marcaciòn con fluor radioactivo
CO7101241A2 (es) Formulaciones de antibióticos
EA201301021A1 (ru) Применение пригодной для распыления композиции, содержащей амброксол

Legal Events

Date Code Title Description
FG Grant, registration